Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Huff

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Environmental and Molecular Mutagenesis|September 9, 2025
Adverse Outcome Pathways Applied to Space Radiation ResearchVinita Chauhan, Veronica S Grybas, Devyn Hoopfer, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Cancer Immunology Research|April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line TreatmentLaura Evgin, Amanda L Huff, Timothy Kottke, et al.
Nature Communications|February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapyChristopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.
JCI Insight|December 8, 2023
CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacyAmanda L Huff, Gabriella Longway, Jacob T Mitchell, et al.
Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Journal of Cardiovascular Imaging|October 16, 2019
Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation TherapySarah A Milgrom, Bibin Varghese, Gregory W Gladish, et al.
Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Environmental and Molecular Mutagenesis|September 9, 2025
Adverse Outcome Pathways Applied to Space Radiation ResearchVinita Chauhan, Veronica S Grybas, Devyn Hoopfer, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Science Translational Medicine|April 13, 2022
Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in miceLaura Evgin, Tim Kottke, Jason Tonne, et al.
Cancer Immunology Research|April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line TreatmentLaura Evgin, Amanda L Huff, Timothy Kottke, et al.
Nature Communications|February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapyChristopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.
JCI Insight|December 8, 2023
CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacyAmanda L Huff, Gabriella Longway, Jacob T Mitchell, et al.
Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Journal of Cardiovascular Imaging|October 16, 2019
Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation TherapySarah A Milgrom, Bibin Varghese, Gregory W Gladish, et al.
Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Pageof 13